News and commentary from the world of neurology and neuroscience
— News and commentary from the world of neurology and neuroscience
by Judy George, Deputy Managing Editor, MedPage Today
May 26, 2026
• 2 min read
The New York Times investigated the rapid expansion in autism therapy clinics in the U.S. with little regulatory oversight. Here are five takeaways from the report.
Pharmalittle: We're reading about a Parkinson's drug setback, a Merck lung cancer therapy, and more
NeuroXT and BIDMC Expand Collaboration to Advance AI-Driven Precision Treatment in Alzheimer's Disease
Novartis says Avidity's science could apply beyond muscular dystrophies
Short Naps, Long Hours: How Autism Clinics Squeeze Medicaid Dollars Out of Preschoolers - Longreads
Earlier treatment with amyloid-targeting therapy linked to better outcomes in Alzheimer’s
ABILITY Neurotech Receives IMDD Approval to Start Clinical Trial for Chronic Implantation of Brain-Computer Interface in ALS Patients
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout
Some people concentrate better with the aid of white noise, music, Ritalin or coffee. Prof. Ari Rappoport was able to focus…
Glint of light in therapy for deadly ALS after decades of struggle New drug shows researchers ‘this illness can be stopped’
NeuroXT and BIDMC Expand Collaboration to Advance AI-Driven Precision Treatment in Alzheimer's Disease
